-
LifeTech Capital On NBY Catheter Research
Tuesday, April 12, 2011 - 9:02am | 88LifeTech Capital has released a report regarding the research done by NovaBay Pharmaceuticals (AMEX: NBY) on urinary catheter blockage and encrustation. According to the report, ” NovaBay Pharmaceuticals presented a poster on the efficacy of its lead Aganocide NVC-422 the for prevention and...
-
J.P. Morgan Reiterates Neutral Rating On BIIB
Tuesday, April 12, 2011 - 8:25am | 208J.P. Morgan is reiterating its Neutral rating on Biogen Idec Inc. (NASDAQ: BIIB) based upon the first of two phase three trials of laquinimod done by Teva Pharmaceutical Industries (NASDAQ: TEVA) in MS patients. According to J.P. Morgan, “The data showed that laquinimod demonstrated a...
-
Benzinga's Top Pre-Market NASDAQ Gainers (EXEL, BIIB, TEVA, CIGX)
Tuesday, April 12, 2011 - 8:19am | 151Exelixis Inc (NASDAQ: EXEL) shares surged 9.95% to $12.15 in the pre-market session. EXEL retained Goldman Sachs in anticipation of potential takeover offers, Bloomberg reported. Biogen Idec Inc (NASDAQ: BIIB) shares advanced 1.21% to $79.50 in the pre-market session. Analysts at BofA/Merrill...
-
Hapoalim Securities Reiterates Buy Rating, $15 PT On VNDA
Tuesday, April 12, 2011 - 8:11am | 123Vanda Pharmaceuticals, Inc. (NASDAQ: VNDA) announced that Novartis (NYSE: NVS) has initiated a Phase 1 study “to evaluate a once-monthly injectable microsphere formulation and an aqueous crystals formulation of Fanapt,” Hapoalim Securities reports. “The pharmacokinetic study will likely be a three...
-
Auxilium Pharma Revenue Of $255-277M And Net Loss of $35-45M (AUXL)
Tuesday, April 12, 2011 - 8:03am | 41In a company 8-K Filing, Auxilium Pharma (NASDAQ: AUXL) sees FY11 revenues of $255-277M vs. $268M estimates, and sees FY11 net income loss of $35-45M vs. a loss of $36M estimate.
-
UPDATE: Oppenheimer Raises PT on Endo Pharmaceuticals to $48 (ENDP)
Tuesday, April 12, 2011 - 7:50am | 159Oppenheimer is out with its report today on Endo Pharmaceuticals (NASDAQ: ENDP), raising its PT from $42 to $48. In a note to clients, Oppenheimer writes, "On 4/11, ENDP announced the ~$2.9B all-cash acquisition of med device manufacturer American Medical Systems (NASDAQ: AMMD). Of note, ENDP's...
-
Duncan Williams Raises ENDP PT To $51
Tuesday, April 12, 2011 - 7:33am | 89Duncan Williams has issued a report raising the Price Target on Endo Pharmaceuticals (NASDAQ: ENDP) from $46 to $51 a share. : Duncan Williams writes, “Endo will now have $1 billion in urology sales, providing scale for more efficient manufacturing, procurement, distribution, and pricing...
-
Oppenheimer Raises PT On Endo Pharmaceuticals To $48
Tuesday, April 12, 2011 - 6:44am | 26Oppenheimer has raised the price target on Endo Pharmaceuticals (NASDAQ: ENDP) from $42 to $48 and maintains its Outperform rating.
-
UBS Downs Elan To Neutral
Tuesday, April 12, 2011 - 6:01am | 40Analysts at UBS downgrade Elan Corporation plc (NYSE: ELN) from “buy” to “neutral.” Elan shares fell 3.18% to close at $7.62 yesterday. More Analyst Ratings here
-
Fast Money Picks For April 12th (EEM, MON, ABT, VZ, MMM)
Monday, April 11, 2011 - 7:18pm | 232On CNBC's Fast Money, Tim Seymour advised investors to sell iShares MSCI Emerging Markets Index (ETF) (NYSE: EEM). He said that its chart looks broken. iShares MSCI Emerging Markets Index (ETF) (EEM) fell 1.18% today, and it closed at $49.45. Zach Karabell wants to buy Monsanto Company (NYSE: MON...
-
FDA Approves Merck's SYLATRON for Injection, a New Adjuvant Treatment for Melanoma with Microscopic or Gross Nodal Involvement
Monday, April 11, 2011 - 5:01pm | 83Merck (NYSE: MRK) today announced that the U.S. Food and Drug Administration (FDA) has approved SYLATRON for injection, for subcutaneous use. SYLATRON is indicated for the adjuvant treatment of melanoma with microscopic or gross nodal involvement within 84 days of definitive surgical resection...
-
DURECT Announces ELADUR Phase II Study Results in Chronic Low Back Pain
Monday, April 11, 2011 - 4:16pm | 112DURECT Corporation (Nasdaq: DRRX) announced today top-line results from a Phase II clinical trial in chronic low back pain for ELADUR, DURECT's proprietary investigational transdermal bupivacaine pain patch. This study was conducted by DURECT's collaborator, King Pharmaceuticals, which is now...
-
DURECT Announces ELADUR Phase II Study Results in Chronic Low Back Pain
Monday, April 11, 2011 - 4:16pm | 116DURECT Corporation (Nasdaq: DRRX) announced today top-line results from a Phase II clinical trial in chronic low back pain for ELADUR(R) (TRANSDUR(R)-Bupivacaine), DURECT's proprietary investigational transdermal bupivacaine pain patch. This study was conducted by DURECT's collaborator, King...
-
BioSpecifics Technologies Corp. Announces Launch of XIAPEX by Pfizer for Treatment of Dupuytren's Contracture in Europe
Monday, April 11, 2011 - 4:08pm | 116BioSpecifics Technologies Corp. (NASDAQ: BSTC) today announced that it will receive a $2.5 million milestone payment as a result of the European launch and first commercial sale of XIAPEX in the United Kingdom, a major European market. Pfizer, Inc. (NYSE: PFE), the EU licensee received approval...
-
Top Percentage Gainers and Losers as of 3:30 p.m. 4/11/2011(TSTY, FLO, GLBC, AMMD, ENDP, CT, EFII, IDIX, MILL, BAC, AFFX, CYH, QUIK, CIGX, THC, BDCO, SCEI, WPRT, IRE, TDSC, GFRE)
Monday, April 11, 2011 - 3:30pm | 553Best 1) Tasty Baking Company (NASDAQ: TSTY): Stock is skyrocketing a remarkable 146.58% to $3.96 in today's action after Flowers Foods (NYSE: FLO) revealed plans to buy the company for $4 per share in an all-cash arrangement. 2) Global Crossing (NASDAQ: GLBC): Surging 58.51% to $23.46 after...